Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;43(6):419-28.
doi: 10.1007/s00535-008-2180-y. Epub 2008 Jul 4.

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

Affiliations
Review

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

Jing-Ting Li et al. J Gastroenterol. 2008.

Abstract

Activation of hepatic stellate cells (HSCs) is the dominant event in liver fibrosis. The early events in the organization of HSC activation have been termed initiation. Initiation encompasses rapid changes in gene expression and phenotype that render the cells responsive to cytokines and other local stimuli. Cellular responses following initiation are termed perpetuation, which encompasses those cellular events that amplify the activated phenotype through enhanced growth factor expression and responsiveness. Multiple cells and cytokines play a part in the regulation of HSC activation. HSC activation consists of discrete phenotype responses, mainly proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis and retinoid loss. Currently, antifibrotic therapeutic strategies include inhibition of HSC proliferation or stimulation of HSC apoptosis, downregulation of collagen production or promotion of its degradation, administration of cytokines, and infusion of mesenchymal stem cells. In this review, we summarize the latest advances in our understanding of the mechanisms of HSC activation and possible antifibrotic therapeutic strategies.

PubMed Disclaimer

References

    1. Hepatology. 2004 Dec;40(6):1304-11 - PubMed
    1. Cancer Res. 2005 Jul 1;65(13):5761-8 - PubMed
    1. Hepatology. 1997 Jan;25(1):2-5 - PubMed
    1. Mol Cell Biol. 2000 Apr;20(8):2818-26 - PubMed
    1. Annu Rev Immunol. 1997;15:675-705 - PubMed

LinkOut - more resources